In this study, we explored combined MAPK and PI3K/AKT/mTOR pathway inhibition with an ATP-competitive mTOR inhibitor, AZD8055, and the allosteric MEK inhibitor, selumetinib, in uveal melanoma cell lines of various genotypic backgrounds. This evidence concerns the gene AKT1 and uveal melanoma.